GENFIT announced positive Phase 1b results for its experimental drug GNS561 combined with a MEK inhibitor in heavily pretreated patients with advanced cholangiocarcinoma (CCA) harboring KRAS mutations. The drug demonstrated a favorable safety and tolerability profile with no dose-limiting toxicities and showed early signs of anti-tumor activity, including disease stabilization in about half of the patients at 6 weeks. Based on these findings, GENFIT plans to expand the Phase 1b study with higher doses and proceed to Phase 2 in the second half of 2026, aiming to address the high unmet medical need in this aggressive cancer with limited treatment options.
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Cardano has introduced native support for BLS12-381 elliptic curve cryptography in its Plutus smart contracts, enabling the verification of thousands of signatures on-chain at a low and predictable cost. This technology compresses multiple signatures...
